Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Study Purpose
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back (recurrent). Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and interfere with the ability of tumor cells to grow and spread. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether giving bevacizumab together with trebananib is more effective than bevacizumab alone in treating brain tumors.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Histologically proven diagnosis of glioblastoma or variants (gliosarcoma, glioblastoma with oligodendroglial features, giant cell glioblastoma); patients will be eligible if the original histology was a lower grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made.
- - The tumor must be supratentorial; patients with infratentorial disease, spinal cord disease, and/or leptomeningeal disease are excluded.
- - Patients must have shown unequivocal evidence for tumor progression on the previous treatment regimen (prior to enrollment on this study) by magnetic resonance imaging (MRI) scan of the brain with and without contrast within 14 days prior to registration; the dose of steroids must be stable or decreasing for at least 5 days prior to the scan; patients with tumor progression who then undergo surgical resection prior to enrollment on study may be eligible as long as pathology confirms progressive or recurrent glioblastoma multiforme (GBM) (or variants); for patients who undergo surgical resection, registration on study may not occur any sooner than 28 days from surgery; an MRI scan of the brain with and without contrast is still required within 14 days prior to registration on study but is not required to demonstrate measurable disease or tumor progression after surgery.
- - Patients unable to undergo MRI because of non-compatible devices can be enrolled, provided computed tomography (CT) scans are obtained and are of sufficient quality; patients without non-compatible devices may not have CT scans performed to meet this requirement.
- - History/physical examination within 14 days prior to registration.
- - Karnofsky performance scale >= 70 within 14 days prior to registration.
- - Patients who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustine, must have confirmation of progressive disease within 14 days prior to registration based upon nuclear imaging, magnetic resonance (MR) spectroscopy, perfusion imaging, or histopathology.
- - Leukocytes > 3,000/mm^3 (within 14 days prior to registration) - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (within 14 days prior to registration) - Hemoglobin >= 10.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dL is acceptable) (within 14 days prior to registration) - Platelets >= 100,000 cells/mm^3 (within 14 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal (within 14 days prior to registration) - Bilirubin =< 2.0 mg/dL (within 14 days prior to registration) - Creatinine within normal upper institutional limits or creatinine clearance > 60 mL/min/1.73 m^2 (per 24 hour urine collection or calculated according to the Cockcroft-Gault formula) for subjects with creatinine levels above the institutional normal (within 14 days prior to registration) - Patients with creatinine levels below normal institutional limits are eligible.
- - Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 (within 14 days prior to registration) - Urinary protein =< 30 mg/dL in urinalysis or =< 1+ on dipstick (within 14 days prior to registration) - Generally well-controlled blood pressure with systolic blood pressure =< 140 mm Hg AND diastolic blood pressure =< 90 mm Hg within 5 days prior to registration; the use of anti-hypertensive medications to control hypertension is permitted.
- - Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) pregnancy test within 14 days prior to registration.
- - Women of childbearing potential and male patients who are sexually active must practice adequate contraception during therapy and for 180 days (6 months) afterwards.
- - Patient must provide study specific informed consent prior to study entry.
Exclusion Criteria:
- - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) - Prior systemic cytotoxic chemotherapy within (i.e., =<) 28 days (42 days for nitrosoureas or mitomycin C) prior to registration, or patients who have not returned to baseline or =< Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v.
- - Patients who received non-cytotoxic drug therapy must be off treatment for at least 14 days prior to registration; prior treatment with anti-vascular endothelial growth factor (VEGF) targeted agents; AMG 386 therapy; or other molecules that inhibit angiopoietins or TEK tyrosine kinase, endothelial (Tie2) receptor including, but not limited to, XL-820, XL-184 (cabozantinib-s-malate), and CVX-060/PF-4856884 is not allowed regardless of time frame.
- - Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments.
- - Treatment within 30 days prior to enrollment with strong immune modulators, including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, lenalidomide, and targeted immune modulators such as abatacept (CTLA-4-Ig), adalimumab, alefacept, anakinra, belatacept (LEA29Y), efalizumab, etanercept, infliximab, or rituximab.
- - Prior radiotherapy within 90 days (3 months) prior to registration unless there is either: a) histopathologic confirmation of recurrent tumor; or b) new enhancement on MRI outside of the radiation treatment field.
- - Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 28 days prior to registration or those patients who receive a non-central nervous system (CNS) minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 3 days prior to registration; there is no waiting period for central line placement; there is a 7-day window for recovery prior to registration for patients who underwent stereotactic biopsy of the brain.
- - Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib, vandetanib, aflibercept, sunitinib, sorafenib, etc.); prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within 30 days prior to enrollment.
- - More than 2 relapses.
- - Therapeutic anticoagulation with warfarin < 7 days prior to registration; (therapeutic or prophylactic therapy with aspirin, a low-molecular weight heparin, or a Factor Xa inhibitor is acceptable) - Intratumoral hemorrhage or peritumoral hemorrhage, demonstrated by MRI or CT scan, CTCAE, v.
- - Gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE, v.
- - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within 180 days (6 months) prior to registration.
- - Transmural myocardial infarction within 180 days (6 months) prior to registration.
- - History of stroke, cerebral vascular accident (CVA), or transient ischemic attack within 180 days (6 months) prior to registration.
- - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
- - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol.
- - Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past.
- - History of non-healing wounds or ulcers, or bone fractures within 90 days (3 months) prior to registration.
- - History of venous or arterial thromboembolism within 12 months prior to registration.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT01609790 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Eudocia Q Lee |
| Principal Investigator Affiliation | NRG Oncology |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH, Other |
| Overall Status | Completed |
| Countries | Canada, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma |
PRIMARY OBJECTIVES:
- I. To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1).
- II. To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).
- I. To further assess the toxicity profile (Cohorts 1 and 2).
- II. To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.
- III. To determine the radiographic response rate (RR), median progression-free survival (PFS), and overall survival (OS) in bevacizumab-naive patients (Cohort 2).
- IV. To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).
- V. To correlate outcome to treatment with tumor genotype, expression profile, and circulating angiogenesis biomarkers in tumor specimens (Cohort 2).
- VI. To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).
- VII. To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).
- I. After completion of study treatment, patients are followed up at 30 days, every 2 months for 1 year, every 6 months for 1 year, and then annually thereafter.
Arms
Experimental: Arm I (bevacizumab and trebananib)
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Active Comparator: Arm II (bevacizumab and placebo)
Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
Interventions
Biological: - Bevacizumab
Given IV
Other: - Laboratory Biomarker Analysis
Correlative studies
Other: - Pharmacological Study
Correlative studies
Other: - Placebo Administration
Given IV
Biological: - Trebananib
Given IV
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Status
Address
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Status
Address
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Status
Address
Katmai Oncology Group
Anchorage, Alaska, 99508
Status
Address
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Status
Address
Arizona Oncology-Deer Valley Center
Phoenix, Arizona, 85027
Status
Address
Arizona Oncology Services Foundation
Scottsdale, Arizona, 85260
Status
Address
Arizona Oncology Associates-West Orange Grove
Tucson, Arizona, 85704
Status
Address
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Status
Address
Mills-Peninsula Medical Center
Burlingame, California, 94010
Status
Address
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Status
Address
Los Angeles County-USC Medical Center
Los Angeles, California, 90033
Status
Address
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Status
Address
Sutter Cancer Research Consortium
Novato, California, 94945
Status
Address
Saint Joseph Hospital - Orange
Orange, California, 92868
Status
Address
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Status
Address
California Pacific Medical Center-Pacific Campus
San Francisco, California, 94115
Status
Address
Sutter Solano Medical Center/Cancer Center
Vallejo, California, 94589
Status
Address
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Status
Address
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Status
Address
The Hospital of Central Connecticut
New Britain, Connecticut, 06050
Status
Address
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut, 06360
Status
Address
William Backus Hospital
Norwich, Connecticut, 06360
Status
Address
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Status
Address
Piedmont Hospital
Atlanta, Georgia, 30309
Status
Address
Piedmont Fayette Hospital
Fayetteville, Georgia, 30214
Status
Address
Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia, 30501
Status
Address
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Status
Address
Rush - Copley Medical Center
Aurora, Illinois, 60504
Status
Address
Northwestern University
Chicago, Illinois, 60611
Status
Address
Rush University Medical Center
Chicago, Illinois, 60612
Status
Address
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Status
Address
Carle on Vermilion
Danville, Illinois, 61832
Status
Address
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Status
Address
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Status
Address
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Status
Address
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Status
Address
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Status
Address
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Status
Address
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Status
Address
Carle Cancer Institute Normal
Normal, Illinois, 61761
Status
Address
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Status
Address
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Status
Address
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Status
Address
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Status
Address
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Status
Address
Carle Cancer Center
Urbana, Illinois, 61801
Status
Address
The Carle Foundation Hospital
Urbana, Illinois, 61801
Status
Address
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
Status
Address
Rush-Copley Healthcare Center
Yorkville, Illinois, 60560
Status
Address
Menorah Medical Center
Overland Park, Kansas, 66209
Status
Address
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Status
Address
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Status
Address
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Status
Address
Maine Medical Center- Scarborough Campus
Scarborough, Maine, 04074
Status
Address
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Status
Address
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Status
Address
Beaumont Hospital - Dearborn
Dearborn, Michigan, 48124
Status
Address
Ascension Saint John Hospital
Detroit, Michigan, 48236
Status
Address
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Status
Address
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Status
Address
Hurley Medical Center
Flint, Michigan, 48503
Status
Address
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Status
Address
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Status
Address
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Status
Address
Borgess Medical Center
Kalamazoo, Michigan, 49048
Status
Address
Sparrow Hospital
Lansing, Michigan, 48912
Status
Address
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Status
Address
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Status
Address
Lake Huron Medical Center
Port Huron, Michigan, 48060
Status
Address
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Status
Address
Ascension Saint Mary's Hospital
Saginaw, Michigan, 48601
Status
Address
William Beaumont Hospital - Troy
Troy, Michigan, 48085
Status
Address
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Fairview Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Status
Address
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Status
Address
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Status
Address
Health Partners Inc
Minneapolis, Minnesota, 55454
Status
Address
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Status
Address
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital
Saint Paul, Minnesota, 55101
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Rice Memorial Hospital
Willmar, Minnesota, 56201
Status
Address
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Status
Address
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Status
Address
Singing River Hospital
Pascagoula, Mississippi, 39581
Status
Address
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Status
Address
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Status
Address
Freeman Health System
Joplin, Missouri, 64804
Status
Address
Mercy Hospital Joplin
Joplin, Missouri, 64804
Status
Address
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Status
Address
North Kansas City Hospital
Kansas City, Missouri, 64116
Status
Address
Heartland Hematology and Oncology Associates Incorporated
Kansas City, Missouri, 64118
Status
Address
Research Medical Center
Kansas City, Missouri, 64132
Status
Address
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Status
Address
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
Status
Address
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Status
Address
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Status
Address
Saint Joseph Oncology Inc
Saint Joseph, Missouri, 64507
Status
Address
Saint Louis Cancer and Breast Institute-South City
Saint Louis, Missouri, 63109
Status
Address
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
Status
Address
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804
Status
Address
Mercy Hospital Springfield
Springfield, Missouri, 65804
Status
Address
CoxHealth South Hospital
Springfield, Missouri, 65807
Status
Address
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Status
Address
New York Oncology Hematology PC - Albany
Albany, New York, 12206
Status
Address
New York Oncology Hematology PC - Albany Medical Center
Albany, New York, 12208
Status
Address
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
Status
Address
Montefiore Medical Center - Moses Campus
Bronx, New York, 10467
Status
Address
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Status
Address
Hematology Oncology Associates of Central New York-Liverpool
Liverpool, New York, 13088
Status
Address
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Status
Address
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Status
Address
Hematology Oncology Associates of Central New York-Rome
Rome, New York, 13440
Status
Address
Hematology Oncology Associates of Central New York-Onondaga Hill
Syracuse, New York, 13215
Status
Address
Mission Hospital
Asheville, North Carolina, 28801
Status
Address
Mountain Radiation Oncology PA
Asheville, North Carolina, 28801
Status
Address
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
Status
Address
Messino Cancer Centers
Asheville, North Carolina, 28806
Status
Address
AdventHealth Hendersonville
Hendersonville, North Carolina, 28792
Status
Address
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Status
Address
Southeast Clinical Oncology Research Consortium NCORP
Winston-Salem, North Carolina, 27104
Status
Address
Summa Health System - Akron Campus
Akron, Ohio, 44304
Status
Address
Cleveland Clinic Akron General
Akron, Ohio, 44307
Status
Address
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Status
Address
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Status
Address
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Status
Address
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Status
Address
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Status
Address
Riverside Methodist Hospital
Columbus, Ohio, 43214
Status
Address
Columbus NCI Community Oncology Research Program
Columbus, Ohio, 43215
Status
Address
Grant Medical Center
Columbus, Ohio, 43215
Status
Address
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Status
Address
Mount Carmel Health Center West
Columbus, Ohio, 43222
Status
Address
Doctors Hospital
Columbus, Ohio, 43228
Status
Address
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Status
Address
Delaware Radiation Oncology
Delaware, Ohio, 43015
Status
Address
Grady Memorial Hospital
Delaware, Ohio, 43015
Status
Address
Fairfield Medical Center
Lancaster, Ohio, 43130
Status
Address
Lancaster Radiation Oncology
Lancaster, Ohio, 43130
Status
Address
Marietta Memorial Hospital
Marietta, Ohio, 45750
Status
Address
Summa Health Medina Medical Center
Medina, Ohio, 44256
Status
Address
Knox Community Hospital
Mount Vernon, Ohio, 43050
Status
Address
Licking Memorial Hospital
Newark, Ohio, 43055
Status
Address
Newark Radiation Oncology
Newark, Ohio, 43055
Status
Address
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Status
Address
University Hospitals Portage Medical Center
Ravenna, Ohio, 44266
Status
Address
Springfield Regional Medical Center
Springfield, Ohio, 45505
Status
Address
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069
Status
Address
Saint Ann's Hospital
Westerville, Ohio, 43081
Status
Address
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio, 43701
Status
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Address
Natalie Warren Bryant Cancer Center at Saint Francis
Tulsa, Oklahoma, 74136
Status
Address
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, 74146
Status
Address
Warren Clinic Oncology-Tulsa
Tulsa, Oklahoma, 74146
Status
Address
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Status
Address
Willamette Valley Cancer Center
Eugene, Oregon, 97401
Status
Address
Providence Portland Medical Center
Portland, Oregon, 97213
Status
Address
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Status
Address
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
Status
Address
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania, 18015
Status
Address
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Status
Address
UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania, 16121
Status
Address
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Status
Address
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania, 15601
Status
Address
Cherry Tree Cancer Center
Hanover, Pennsylvania, 17331
Status
Address
UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania, 15901
Status
Address
Lancaster General Hospital
Lancaster, Pennsylvania, 17602
Status
Address
UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania, 15132
Status
Address
UPMC Cancer Center-Natrona Heights
Natrona Heights, Pennsylvania, 15065
Status
Address
UPMC Jameson
New Castle, Pennsylvania, 16105
Status
Address
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Status
Address
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Status
Address
UPMC-Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213
Status
Address
UPMC-Saint Margaret
Pittsburgh, Pennsylvania, 15215
Status
Address
UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania, 15232
Status
Address
UPMC Jefferson Regional Radiation Oncology
Pittsburgh, Pennsylvania, 15236
Status
Address
UPMC-Passavant Hospital
Pittsburgh, Pennsylvania, 15237
Status
Address
UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania, 15243
Status
Address
UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania, 16346
Status
Address
UPMC Uniontown Hospital Radiation Oncology
Uniontown, Pennsylvania, 15401
Status
Address
UPMC Washington Hospital Radiation Oncology
Washington, Pennsylvania, 15301
Status
Address
Reading Hospital
West Reading, Pennsylvania, 19611
Status
Address
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Status
Address
Main Line Health NCORP
Wynnewood, Pennsylvania, 19096
Status
Address
WellSpan Health-York Hospital
York, Pennsylvania, 17403
Status
Address
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Status
Address
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Status
Address
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
Texas Oncology-Austin Midtown
Austin, Texas, 78705
Status
Address
Texas Oncology - Central Austin Cancer Center
Austin, Texas, 78731
Status
Address
Texas Oncology - South Austin Cancer Center
Austin, Texas, 78745
Status
Address
Texas Oncology Bedford
Bedford, Texas, 76022
Status
Address
Texas Oncology at Baylor Charles A Sammons Cancer Center
Dallas, Texas, 75246
Status
Address
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Status
Address
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, 76104
Status
Address
Texas Oncology-Grapevine
Grapevine, Texas, 76053
Status
Address
Texas Oncology-Longview Cancer Center
Longview, Texas, 75601
Status
Address
Texas Oncology-Seton Williamson
Round Rock, Texas, 78665
Status
Address
Texas Oncology - Round Rock Cancer Center
Round Rock, Texas, 78681
Status
Address
Texas Oncology Cancer Center Sugar Land
Sugar Land, Texas, 77479
Status
Address
Tyler Cancer Center
Tyler, Texas, 75702
Status
Address
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Status
Address
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Status
Address
Logan Regional Hospital
Logan, Utah, 84321
Status
Address
Intermountain Medical Center
Murray, Utah, 84107
Status
Address
McKay-Dee Hospital Center
Ogden, Utah, 84403
Status
Address
Utah Valley Regional Medical Center
Provo, Utah, 84604
Status
Address
Saint George Regional Medical Center
Saint George, Utah, 84770
Status
Address
Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah, 84106
Status
Address
LDS Hospital
Salt Lake City, Utah, 84143
Status
Address
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Status
Address
Cancer Care Northwest-North Spokane
Spokane, Washington, 99218
Status
Address
PeaceHealth Southwest Medical Center
Vancouver, Washington, 98664
Status
Address
Compass Oncology Vancouver
Vancouver, Washington, 98684
Status
Address
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Status
Address
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Status
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Address
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Status
Address
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Status
Address
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792
Status
Address
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Status
Address
Bay Area Medical Center
Marinette, Wisconsin, 54143
Status
Address
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
Status
Address
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Address
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
Status
Address
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
Status
Address
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
Status
Address
Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls, Wisconsin, 54154
Status
Address
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235-1495
Status
Address
Green Bay Oncology - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
Status
Address
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Status
Address
Aspirus Regional Cancer Center
Wausau, Wisconsin, 54401
International Sites
Status
Address
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
